Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 11Thoracic 5Genitourinary 4CNS 4Gynecologic 3Breast 3Other hematologic neoplasm 2Tumor-Agnostic 1Sarcoma 1Plasma cell 1Other neoplasm 1NET 1Lymphoid 1Head & Neck 1Endocrine 1Dermatologic 1Classical hematology 1

Conditions

Pancreatic Neuroendocrine Tumors (pNET) 1

Interventions

Everolimus 7lutetium Lu 177 dotatate 6lanreotide 5Octreotide 5177Lu-octreotide, DOTA(0)-Tyr(3)- 4amino-acid, glucose, and electrolyte solution 3Capecitabine 3surufatinib 2pasireotide 2fluorodopa F 18 2Temozolomide 2Lutetium-177 2Lutetium 2Introns 2Ga(III)-DOTATOC 2telotristat ethyl 1pembrolizumab 1copper dotatate CU-64 1cabozantinib 1X-Rays 1Watchful Waiting 1Sunitinib 1Specimen Handling 1Somatostatin 1Serotonin 1Salts 1Receptor-Like Protein Tyrosine Phosphatases, Class 2 1Phantoms, Imaging 1Oxaliplatin 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Watchful Waiting × NET × Clear all
NCT07591493 2026-05-15

ADJUPANET

Gustave Roussy, Cancer Campus, Grand Paris

Phase 3 Not yet recruiting
300 enrolled
EndocrineGastrointestinalNET

Pancreatic Neuroendocrine Tumors (pNET)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡